CDK4 and neoplasm: As cell cycle inhibitors, CDK4/6i decrease T cell proliferation; however, CDK4/6i increase the activation of effector T cells and modulate gene expression.57,60 Preclinical and clinical studies have confirmed increased tumor infiltrating T cells61 and decreased Tregs within treated tumors.56,57,60,61